While Arcturus Therapeutics Holdings Inc has underperformed by -1.79%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARCT fell by -62.18%, with highs and lows ranging from $45.00 to $14.11, whereas the simple moving average fell by -31.98% in the last 200 days.
On January 28, 2025, BTIG Research started tracking Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) recommending Buy. A report published by Leerink Partners on August 12, 2024, Initiated its previous ‘Outperform’ rating for ARCT. Canaccord Genuity also rated ARCT shares as ‘Buy’, setting a target price of $90 on the company’s shares in an initiating report dated December 13, 2023. William Blair Initiated an Outperform rating on July 24, 2023, and assigned a price target of $71. H.C. Wainwright May 11, 2023d its ‘Neutral’ rating to ‘Buy’ for ARCT, as published in its report on May 11, 2023. Wells Fargo’s report from November 14, 2022 suggests a price prediction of $35 for ARCT shares, giving the stock a ‘Overweight’ rating. Robert W. Baird also rated the stock as ‘Underperform’.
Analysis of Arcturus Therapeutics Holdings Inc (ARCT)
Further, the quarter-over-quarter decrease in sales is -25.56%, showing a negative trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Arcturus Therapeutics Holdings Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -31.16% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.67, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and ARCT is recording an average volume of 410.61K. On a monthly basis, the volatility of the stock is set at 7.25%, whereas on a weekly basis, it is put at 6.83%, with a loss of -8.86% over the past seven days. Furthermore, long-term investors anticipate a median target price of $72.62, showing growth from the present price of $14.29, which can serve as yet another indication of whether ARCT is worth investing in or should be passed over.
How Do You Analyze Arcturus Therapeutics Holdings Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 10.14%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 89.67% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ARCT shares are owned by institutional investors to the tune of 89.67% at present.
